Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Aim: To evaluate the efficacy and safety of saxagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Methods: In this multicentre, randomized, parallel‐group, double‐blind, placebo‐controlled study, patients with glycated haemoglobin (HbA1c) 7–11% and creatinine...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2011-06, Vol.13 (6), p.523-532
Main Authors: Nowicki, M., Rychlik, I., Haller, H., Warren, M. L., Suchower, L., Gause-Nilsson, I.
Format: Article
Language:English
Subjects:
Adamantane - analogs & derivatives
Adamantane - therapeutic use
Aged
Blood Glucose - drug effects
Creatinine
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Nephropathies - blood
Diabetic Nephropathies - drug therapy
Dipeptides - therapeutic use
dipeptidyl peptidase-4 inhibitor
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
Double-Blind Method
end-stage renal disease
Female
glycaemic control
Glycated Hemoglobin A - drug effects
Hemodialysis
Hemoglobin
Humans
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - drug therapy
Male
Middle Aged
Placebos
renal impairment
saxagliptin
Treatment Outcome
type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To evaluate the efficacy and safety of saxagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Methods: In this multicentre, randomized, parallel‐group, double‐blind, placebo‐controlled study, patients with glycated haemoglobin (HbA1c) 7–11% and creatinine clearance
ISSN:1462-8902
1463-1326
DOI:10.1111/j.1463-1326.2011.01382.x